Why Pharma Programs Slip: The Governance Gaps Nobody Talks About

Every delayed drug launch has a story. The official narrative usually involves technical complications — a formulation challenge, a manufacturing scale-up issue, a clinical endpoint that took longer to achieve than modeled. Those factors are real. But underneath them, in nearly every case, is a governance failure that allowed problems to grow undetected until they were too expensive to quietly absorb.

This post examines the most common governance gaps that cause pharma programs to slip — and why they are so frequently overlooked until the damage is done.

Decisions That Never Get Made

The most underappreciated cause of program delay is not technical risk — it is decision latency. When a team identifies a problem and the escalation path is unclear, or when the right decision-makers are not in the right forum, decisions sit. Every day a decision sits is a day the program does not move.

In well-governed programs, decision rights are explicit. Teams know who can approve what, within what parameters, and on what timeline. Escalations have defined triggers and clear owners. Decision forums meet on cadences that match the program's pace.

In programs that slip, decisions often require consensus from people who are not accountable for outcomes, go through approval chains designed for lower-risk operational choices, or simply never get formally made because "everyone assumed someone else handled it."

The Plan That Only Exists on Paper

Integrated program plans that are not actively maintained are among the most common contributors to schedule surprise. Teams often build a detailed plan at program initiation, then manage against a simplified version that loses important interdependencies over time.

When a delay occurs in one workstream, the team updates that workstream's timeline — but does not cascade the impact through connected workstreams. The cumulative effect of these small adjustments is invisible until the gap between the plan and reality becomes undeniable.

Active program planning requires someone accountable for maintaining the integrated view, and leadership that uses the plan as a live tool rather than a reference document.

Risk Registers That Do Not Drive Action

Most pharma programs have risk registers. Very few use them well.

A risk register that is updated quarterly, reviewed in a 20-minute slot at the end of a steering committee meeting, and organized around risks that felt concerning at program initiation is not a risk management tool. It is a documentation artifact.

Effective risk management identifies new risks as they emerge, quantifies their potential schedule and cost impact, assigns clear mitigation owners, and tracks those mitigations to completion. Risk registers should be living documents that leadership takes seriously — not tables that get refreshed before milestone reviews.

Scope That Drifts Without Accountability

Scope creep is a familiar concept in project management, but in pharmaceutical programs it often operates differently than in other industries. The additions are frequently justified — a request from a key clinical partner, a regulatory intelligence insight that suggests expanding the study population, a manufacturing improvement that seems worth incorporating. Each individual decision is defensible. The aggregate effect on timeline and budget is not.

Strong governance includes explicit scope management: a baseline that is formally documented, a change process that evaluates each addition against its schedule and cost implications, and leadership that is willing to defer good ideas to a future phase when the current program needs to stay on track.

What Good Governance Looks Like in Practice

Programs that consistently execute on time and on budget share common characteristics. Integrated program plans are maintained and used. Decision rights are clear and decision forums are effective. Risk management is active and visible to leadership. Scope changes are managed as real choices with real tradeoffs.

None of this is complicated in concept. It requires discipline, accountability, and leadership that insists on it.

If your programs are slipping and you are not sure whether the root cause is technical or governance-related, the answer is almost always both — and the governance problem is the one that is easier to fix.

Readiness Consulting Group provides program governance support to pharmaceutical and biotech organizations navigating complex programs. Reach us at readinessconsultinggroup.com/get-started.